Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study aims to unlock secrets of early blood cancers

NCT ID NCT02269592

Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal is to better understand why these cancers develop and how to improve treatment and prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2014

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Known or Suspected Precursor Hematological Cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Known or Suspected Precursor Hematological Cancer * Including the following subgroups of diseases: * Early MDS, including pathologically-confirmed MDS (IPSS Low/Int-1; IPSS-R Very Low/Low) and idiopathic cytopenias of undetermined significance (ICUS); * Asymptomatic Multiple Myeloma and Waldenstrom Macroglobulinemia such as monoclonal gammopathy of undermined significance (MGUS) or Smoldering Multiple Myeloma (SMM or SWM); * Monoclonal B cell lymphocytosis (MBL); * Early stage asymptomatic low-grade lymphomas; or * Other precursor conditions or clonal genetic abnormalities of the blood/bone marrow that do not meet criteria for symptomatic hematological malignancy, or patients exposed to prior chemotherapies (e. g., alkylating agents, platinum derivatives, taxanes, topo-2 inhibitors, anti-metabolites, systemic radioisotopes). * Patients must be at least 18 years of age to participate in this research. * Inclusion of Women and Minorities -- In accordance with NIH guidelines, women and members of minority groups and their subpopulations will be included in this protocol. Exclusion Criteria: * Patients with Known or Suspected Precursor Hematological Cancer are NOT EXCLUDED * Evidence of symptomatic or active hematological malignancy. Patients enrolled on clinical trials for precursor diseases are NOT excluded from this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell malignancy, low-grade are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell chronic lymphocytic leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm indolent B-cell non-Hodgkin lymphoma leukemia, chronic lymphocytic, susceptibility to, 2 monoclonal gammopathy of uncertain significance myelodysplastic syndrome Myelodysplastic Syndromes premalignant hematological system disease Smoldering Multiple Myeloma smoldering plasma cell myeloma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-cell malignancy, low-grade Hematological malignancies IgG monoclonal gammopathy of uncertain significance Monoclonal gammopathy of undetermined significance (MGUS) Myelodysplastic syndrome with low-grade lesions Myelodysplastic syndromes Smoldering multiple myeloma Waldenstrom macroglobulinemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dana Farber Cancer Institute at Merrimack Valley

    RECRUITING

    Methuen, Massachusetts, 01844, United States

  • Dana Farber Cancer Institute at Milford Regional Medical Center

    RECRUITING

    Milford, Massachusetts, 01757, United States

  • Dana Farber Cancer Institute at South Shore

    RECRUITING

    Weymouth, Massachusetts, 02190, United States

  • Dana Farber Cancer Institute at St. Elizabeth's

    RECRUITING

    Brighton, Massachusetts, 02135, United States

  • Dana Farber/New Hampshire Oncology-Hematology

    RECRUITING

    Londonderry, New Hampshire, 03053, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • West Michigan Cancer Center

    RECRUITING

    Kalamazoo, Michigan, 49007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.